Compare ESNT & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESNT | IMVT |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.3B |
| IPO Year | 2013 | N/A |
| Metric | ESNT | IMVT |
|---|---|---|
| Price | $65.79 | $25.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $68.00 | $25.29 |
| AVG Volume (30 Days) | 648.5K | ★ 2.0M |
| Earning Date | 02-13-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.87 | N/A |
| Revenue | ★ $1,263,558,000.00 | N/A |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $1.55 | N/A |
| P/E Ratio | $9.56 | ★ N/A |
| Revenue Growth | ★ 2.04 | N/A |
| 52 Week Low | $51.61 | $12.72 |
| 52 Week High | $67.09 | $27.69 |
| Indicator | ESNT | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 52.14 |
| Support Level | $65.41 | $26.35 |
| Resistance Level | $66.11 | $27.64 |
| Average True Range (ATR) | 0.99 | 1.41 |
| MACD | 0.01 | -0.15 |
| Stochastic Oscillator | 73.21 | 54.10 |
Essent Group Ltd serves the housing finance industry by providing private mortgage insurance, reinsurance, risk management products, title insurance, and settlement services to mortgage lenders, borrowers, and investors to support homeownership. It provides credit protection to lenders and mortgage investors by covering a portion of the unpaid principal balance of a mortgage and certain related expenses in the event of a default. By providing capital to mitigate mortgage credit risk, the company allows lenders to make additional mortgage financing available to prospective homeowners.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.